HUP0104046A3 - Adenovirus-mediated gene therapy - Google Patents

Adenovirus-mediated gene therapy

Info

Publication number
HUP0104046A3
HUP0104046A3 HU0104046A HUP0104046A HUP0104046A3 HU P0104046 A3 HUP0104046 A3 HU P0104046A3 HU 0104046 A HU0104046 A HU 0104046A HU P0104046 A HUP0104046 A HU P0104046A HU P0104046 A3 HUP0104046 A3 HU P0104046A3
Authority
HU
Hungary
Prior art keywords
adenovirus
gene therapy
mediated gene
mediated
therapy
Prior art date
Application number
HU0104046A
Other languages
English (en)
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104046(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of HUP0104046A2 publication Critical patent/HUP0104046A2/hu
Publication of HUP0104046A3 publication Critical patent/HUP0104046A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU0104046A 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy HUP0104046A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (2)

Publication Number Publication Date
HUP0104046A2 HUP0104046A2 (hu) 2002-01-28
HUP0104046A3 true HUP0104046A3 (en) 2003-09-29

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104046A HUP0104046A3 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Country Status (18)

Country Link
US (1) US6579855B1 (hu)
EP (1) EP1135513B2 (hu)
JP (1) JP4733833B2 (hu)
KR (1) KR20020013473A (hu)
CN (1) CN1184321C (hu)
AT (1) ATE341639T1 (hu)
AU (1) AU749451B2 (hu)
CA (1) CA2348624C (hu)
CY (1) CY1106198T1 (hu)
DE (1) DE69933468T3 (hu)
DK (1) DK1135513T4 (hu)
ES (1) ES2273521T5 (hu)
GB (1) GB9824437D0 (hu)
HU (1) HUP0104046A3 (hu)
NO (1) NO330776B1 (hu)
PL (1) PL193076B1 (hu)
PT (1) PT1135513E (hu)
WO (1) WO2000028059A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
MX367842B (es) 2012-02-07 2019-09-09 Global Bio Therapeutics Inc Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo.
EP2994168A4 (en) * 2013-05-08 2016-10-05 Finvector Vision Therapies Ltd TREATMENT OF HIGH-GRADE GLIOMA OPERABLE BY GENE THERAPY BASED ON SITIMAGEN CÉRADENOVEC AND GANCICLOVIR
ES2733911T3 (es) 2013-08-08 2019-12-03 Global Bio Therapeutics Inc Dispositivo de sujeción para procedimientos minimamente invasivos
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
JP2023510115A (ja) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規ｉｌ２アゴニストおよびそれらの使用方法
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
KR20240035845A (ko) 2021-07-19 2024-03-18 리제너론 파아마슈티컬스, 인크. Il12 수용체 효능제 및 그의 사용 방법
AU2022383847A1 (en) 2021-11-11 2024-06-20 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
DK1135513T4 (da) 2011-11-21
NO20012220L (no) 2001-05-04
JP4733833B2 (ja) 2011-07-27
PT1135513E (pt) 2006-12-29
EP1135513A1 (en) 2001-09-26
AU749451B2 (en) 2002-06-27
AU1385100A (en) 2000-05-29
JP2002529097A (ja) 2002-09-10
GB9824437D0 (en) 1999-01-06
CA2348624A1 (en) 2000-05-18
NO20012220D0 (no) 2001-05-04
EP1135513B2 (en) 2011-08-10
CN1184321C (zh) 2005-01-12
CA2348624C (en) 2012-07-31
NO330776B1 (no) 2011-07-11
DK1135513T3 (da) 2006-11-27
ES2273521T3 (es) 2007-05-01
WO2000028059A1 (en) 2000-05-18
HUP0104046A2 (hu) 2002-01-28
CN1325450A (zh) 2001-12-05
US6579855B1 (en) 2003-06-17
EP1135513B1 (en) 2006-10-04
DE69933468T3 (de) 2012-01-19
PL349489A1 (en) 2002-07-29
PL193076B1 (pl) 2007-01-31
ATE341639T1 (de) 2006-10-15
ES2273521T5 (es) 2011-12-28
CY1106198T1 (el) 2011-06-08
KR20020013473A (ko) 2002-02-20
DE69933468D1 (de) 2006-11-16
DE69933468T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
GB9622500D0 (en) Therapeutic gene
HUP0104046A3 (en) Adenovirus-mediated gene therapy
EP1077996A4 (en) GENE EDG3sb HUMAN
PL345207A1 (en) Gene therapy method
GB9700939D0 (en) Therapy
GB9816556D0 (en) Therapy
PL340374A1 (en) Tanatin encoding gene
EP1181365A4 (en) PRP TYPE GENE
GB9924981D0 (en) Gene therapy
EP1038957A4 (en) GENE TSA305
GB9900009D0 (en) Gene therapy
EP1084236A4 (en) NOVEL ADENOVIRAL VECTORS FOR GENE THERAPY
GB0406539D0 (en) Gene therapy
EP1215284A4 (en) TSG TYPE GENE
GB9724828D0 (en) Gene
AU4552700A (en) Gene therapy
GB2333527B (en) Therapeutic gene
GB9920837D0 (en) Gene therapy
GB9910587D0 (en) Gene therapy
EP1135022A4 (en) PLASTINPROMOTER-CONDUCTED GENE THERAPY
GB9806039D0 (en) Therapy
GB9709003D0 (en) Gene
GB9722238D0 (en) Gene
GB9718029D0 (en) Gene
GB9819826D0 (en) Gene therapy method

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal